挽救治疗包括膦甲酸钠和ibalizumab 用于治疗多种药物耐药的人类免疫缺陷病毒 2 型感染。

Salvage Therapy Including Foscarnet and Ibalizumab for Multidrug-Resistant Human Immunodeficiency Virus Type 2 Infection.

机构信息

Assistance Publique-Hôpitaux de Paris.Nord, Service des Maladies Infectieuses et Tropicales, Hôpitaux Universitaires Paris Nord Val de Seine, site Bichat-Claude Bernard, Paris, France.

Assistance Publique-Hôpitaux de Paris.Nord, Service de Virologie, Hôpitaux Universitaires Paris Nord Val de Seine, site Bichat-Claude Bernard, Paris, France.

出版信息

Clin Infect Dis. 2024 Apr 10;78(4):1005-1010. doi: 10.1093/cid/ciad695.

DOI:10.1093/cid/ciad695

PMID:38630945

Abstract

We evaluated Ibalizumab (IBA)-containing standardized optimized salvage regimen (with or without a 4-week foscarnet induction) in individuals harboring multidrug-resistant human immunodeficiency virus type 2 (HIV-2). Nine were included; 2 achieved virological suppression after foscarnet induction with a sustained suppression at Week 24 after IBA initiation, and an additional individual at Week 24 after Ibalizumab initiation.

摘要

我们评估了含有伊巴利珠单抗（IBA）的标准化优化挽救方案（含或不含 4 周膦甲酸钠诱导）在携带多重耐药性人类免疫缺陷病毒 2 型（HIV-2）的个体中的疗效。共纳入 9 例患者；2 例在膦甲酸钠诱导后实现病毒学抑制，且在伊巴利珠单抗起始后 24 周持续抑制；另有 1 例在伊巴利珠单抗起始后 24 周实现抑制。